148 related articles for article (PubMed ID: 30337449)
1. The second recurrence of
Kwon BS; Shim TS; Jo KW
Eur Respir J; 2019 Jan; 53(1):. PubMed ID: 30337449
[No Abstract] [Full Text] [Related]
2. Risk factors for recurrence after successful treatment of Mycobacterium avium complex lung disease.
Lee BY; Kim S; Hong Y; Lee SD; Kim WS; Kim DS; Shim TS; Jo KW
Antimicrob Agents Chemother; 2015; 59(6):2972-7. PubMed ID: 25753634
[TBL] [Abstract][Full Text] [Related]
3. Treatment Duration and Disease Recurrence Following the Successful Treatment of Patients With Mycobacterium avium Complex Lung Disease.
Furuuchi K; Morimoto K; Kurashima A; Fujiwara K; Nakamoto K; Tanaka Y; Tachibana H; Yoshimori K; Sasaki Y; Ohta K
Chest; 2020 Jun; 157(6):1442-1445. PubMed ID: 31954692
[No Abstract] [Full Text] [Related]
4. Treatment of pulmonary disease caused by Mycobacterium avium complex.
Shimokata K
Intern Med; 2003 Aug; 42(8):627-8. PubMed ID: 12924480
[No Abstract] [Full Text] [Related]
5. Intermittent Antibiotic Therapy for Recurrent Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease.
Jhun BW; Moon SM; Kim SY; Park HY; Jeon K; Kwon OJ; Huh HJ; Ki CS; Lee NY; Chung MJ; Lee KS; Shin SJ; Daley CL; Koh WJ
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203483
[TBL] [Abstract][Full Text] [Related]
6. Determinants of recurrence after successful treatment of Mycobacterium avium complex lung disease.
Min J; Park J; Lee YJ; Kim SJ; Park JS; Cho YJ; Yoon HI; Lee CT; Lee JH
Int J Tuberc Lung Dis; 2015 Oct; 19(10):1239-45. PubMed ID: 26459540
[TBL] [Abstract][Full Text] [Related]
7. Rifampicin has no role in treatment of
van Ingen J; Hoefsloot W; Dartois V; Dick T
Eur Respir J; 2024 May; 63(5):. PubMed ID: 38697635
[TBL] [Abstract][Full Text] [Related]
8. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates.
Kobashi Y; Yoshida K; Miyashita N; Niki Y; Oka M
J Infect Chemother; 2006 Aug; 12(4):195-202. PubMed ID: 16944258
[TBL] [Abstract][Full Text] [Related]
9. Development of Macrolide Resistance and Reinfection in Refractory Mycobacterium avium Complex Lung Disease.
Jhun BW; Kim SY; Moon SM; Jeon K; Kwon OJ; Huh HJ; Ki CS; Lee NY; Shin SJ; Daley CL; Koh WJ
Am J Respir Crit Care Med; 2018 Nov; 198(10):1322-1330. PubMed ID: 29877739
[TBL] [Abstract][Full Text] [Related]
10. Mycobacterium avium complex lung disease and panhypopituitarism.
Koh WJ; Kwon OJ
Mayo Clin Proc; 2005 Jul; 80(7):961-2. PubMed ID: 16007905
[No Abstract] [Full Text] [Related]
11. Association Between Duration of Aminoglycoside Treatment and Outcome of Cavitary Mycobacterium avium Complex Lung Disease.
Kim OH; Kwon BS; Han M; Koh Y; Kim WS; Song JW; Oh YM; Lee SD; Lee SW; Lee JS; Lim CM; Choi CM; Huh JW; Hong SB; Shim TS; Jo KW
Clin Infect Dis; 2019 May; 68(11):1870-1876. PubMed ID: 30239615
[TBL] [Abstract][Full Text] [Related]
12. Mycobacterium Growth Indicator Tube Time-To-Positivity Can Serve As an Early Biomarker of Treatment Response in Mycobacterium avium Complex Pulmonary Disease.
Danho R; Schildkraut JA; Zweijpfenning SMH; Svensson EM; Pennings LJ; Kuipers S; Wertheim HFL; Boeree MJ; Hoefsloot W; van Ingen J
Chest; 2022 Feb; 161(2):370-372. PubMed ID: 34391756
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of intermittent maintenance therapy after successful treatment of Mycobacterium avium complex lung disease.
Asakura T; Nakagawa T; Suzuki S; Namkoong H; Morimoto K; Ishii M; Kurashima A; Betsuyaku T; Ogawa K; Hasegawa N;
J Infect Chemother; 2019 Mar; 25(3):218-221. PubMed ID: 30172726
[TBL] [Abstract][Full Text] [Related]
14. Host susceptibility or environmental exposure in Mycobacterium avium complex lung disease: it takes two to tango.
Marras TK
Am J Respir Crit Care Med; 2012 Oct; 186(7):585-6. PubMed ID: 23027852
[No Abstract] [Full Text] [Related]
15. Clarithromycin treatment for Mycobacterium avium-intracellulare complex lung disease.
Frothingham R
Am J Respir Crit Care Med; 1996 Jun; 153(6 Pt 1):1990-1. PubMed ID: 8665069
[No Abstract] [Full Text] [Related]
16. Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease.
Koh WJ; Jeong BH; Jeon K; Lee SY; Shin SJ
Am J Respir Crit Care Med; 2012 Oct; 186(8):797-802. PubMed ID: 22878282
[TBL] [Abstract][Full Text] [Related]
17. Response to Switch from Intermittent Therapy to Daily Therapy for Refractory Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease.
Koh WJ; Jeong BH; Jeon K; Park HY; Kim SY; Huh HJ; Ki CS; Lee NY; Shin SJ; Daley CL
Antimicrob Agents Chemother; 2015 Aug; 59(8):4994-6. PubMed ID: 25987622
[TBL] [Abstract][Full Text] [Related]
18. Natural history of
Hwang JA; Kim S; Jo KW; Shim TS
Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28275170
[TBL] [Abstract][Full Text] [Related]
19. The natural history of non-cavitary nodular bronchiectatic Mycobacterium avium complex lung disease.
Kwon BS; Lee JH; Koh Y; Kim WS; Song JW; Oh YM; Lee SD; Lee SW; Lee JS; Lim CM; Choi CM; Huh JW; Hong SB; Shim TS; Jo KW
Respir Med; 2019 Apr; 150():45-50. PubMed ID: 30961950
[TBL] [Abstract][Full Text] [Related]
20. Mycobacterium avium disease: progress at last.
Bates JH
Am J Respir Crit Care Med; 1996 Jun; 153(6 Pt 1):1737-8. PubMed ID: 8665029
[No Abstract] [Full Text] [Related]
[Next] [New Search]
